0.00Open1.10Pre Close0 Volume5 Open Interest3.00Strike Price0.00Turnover87.33%IV3.40%PremiumJan 17, 2025Expiry Date0.97Intrinsic Value100Multiplier25DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.9019Delta0.1922Gamma4.07Leverage Ratio-0.0034Theta0.0018Rho3.67Eff Leverage0.0018Vega
Trevi Therapeutics Stock Discussion
📊⚡️📊
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Thursday, 12th December at 7:30 am
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160
The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 20...
Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough
No comment yet